The impact of cerebrovascular steno-occlusive disease subtype on surgical and clinical outcomes after direct STA-MCA bypass surgery.

Objective: Although well-established in moyamoya disease (MMD), the role of direct superficial temporal artery (STA) to middle cerebral artery (MCA) bypass in non-MMD (N-MMD) cerebrovascular steno-occlusive syndromes remains controversial. Nonetheless, the recurrent stroke risk in patients with N-MMD, despite best medical management, remains exceedingly high-especially for those suffering from hypoperfusion-related ischemia. The study objective was to determine the relative safety and efficacy profiles of direct STA-MCA bypass surgery for MMD and N-MMD patients in a large contemporary cohort.

Unusual bone abnormalities from therapeutic ultrasound diathermy: a radiological case report.

This report describes bone marrow abnormalities arising as a consequence of therapeutic ultrasound diathermy, which are an uncommon diagnostic entity. Over the period from 2018 to 2023, 11 patients were identified that showed abnormalities of the bone marrow on MRI, as a direct result of ultrasound diathermy treatment. These abnormalities displayed consistent imaging features, characterized by areas of low T1W and high T2W signal intensity with well-demarcated geographic margins and central fatty areas, as can be seen in bone infarction.

First Report of on Soybean in Germany.

(anamorph: ) species are endophytes or fungal pathogens for many different plant species. Soybean () can be infected by many different species; among them, and are responsible for the most significant damages. is a species that was only recently described and has so far been found on sunflower () in Australia and an unknown host in Thailand.

Molecular adaptation to neoadjuvant immunotherapy in triple-negative breast cancer.

Therapy-induced molecular adaptation of triple-negative breast cancer is crucial for immunotherapy response and resistance. We analyze tumor biopsies from three different time points in the randomized neoadjuvant GeparNuevo trial (NCT02685059), evaluating the combination of durvalumab with chemotherapy, for longitudinal alterations of gene expression. Durvalumab induces an activation of immune and stromal gene expression as well as a reduction of proliferation-related gene expression.